ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in advanced/recurrent endometrial cancer

ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in advanced/recurrent endometrial cancer ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in advanced/recurrent endometrial cancer Mansoor Raza Mirza, MD Study Chair & Medical Direcor of NSGO-CTU ENGOT, NSGO-CTU & GOG-Foundation proudly announce the ground-breaking results of ENGOT-EN6-NSGO/GOG-3031/RUBY trial. The results reveal improvement in overall survival at […]

New PM – Karen Stampe Petersson

Welcome to our new Project Manager Karen Stampe Petersson  has a Master of Science (MSc) in Biotechnology and has been working at the Laboratory for Molecular Cardiology at the Heart Centre of Rigshospitalet, Copenhagen University Hospital prior to NSGO-CTU. We’re very excited to have her join out team. arrow-icon-size3 Back To Overview

INOVATYON/ ENGOT-ov5 Trial publication

Results from the MaNGO lead study INOVATYON/ ENGOT-ov5 The Novemeber edition of the American Society of Clinical Oncology has published: INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line   With contributions […]

New NSGO-CTU collaboration with Kancera

We are very happy to announce that Kancera will collaborate with the Nordic Society of Gynaecological Oncology in our upcoming ovarian cancer study! “Women with far progressed ovarian cancer that experience relapse from platinum chemotherapy has very few treatment options left. The opportunity for KAND567 to restore platinum sensitivity is, even though at an early […]

ENGOT Workshop in Malaga

ENGOT Workshop in Malaga The 2022 GCA edition is organized by ENGOT in cooperation with the European Network of Young Gynae Oncologists (ENYGO) and is designed to help senior investigators to experience the clinical trial leader role as well as to young clinicians to gain knowledge within the clinical trial community. arrow-icon-size3 Back To Overview